心血管疾患に対する繊維酸の効果:体系的なレビューとメタ解析
Min Jun1, Celine Foote, Jicheng Lv
1The George Institute for International Health, University of Sydney, Sydney, Australia.
Lancet (London, England)
|May 14, 2010
まとめ
繊維酸は,主に冠動脈イベントを予防することによって,主要な心血管イベントを大幅に軽減します. これらの薬は,心臓血管疾患のリスクが高い人,または併合性脂質不全症の個人に有益であり,重篤な有害事象のリスクが増加することはありません.
科学分野:
- 心臓病学 心臓病学
- 薬理学 薬理学とは
- クリニック・トライアル 臨床試験
背景:
- 繊維酸が心血管疾患のリスクに与える影響について,矛盾する研究結果があります.
- これらの効果を明らかにするために,体系的なレビューとメタ解析が行われました.
研究 の 目的:
- 主要な臨床心血管疾患における線維治療の効果を調査する.
- 死率,特定の心血管疾患,および有害事象に対する繊維酸の影響を評価する.
主な方法:
- Medline,Embase,Cochrane Libraryのランダム化対照試験 (RCT) の体系的な検索は,2010年3月まで行われました.
- フィブラットとプラセボを比較した45,058人の参加者を含む18件のRCTの含有.
- 相対リスク (RR) 削減の概要的な見積もりを計算するために使用されるランダム効果モデル.
主要な成果:
- 繊維剤は,主要心血管イベント (p=0.048) で10%のRR低下,冠動脈イベント (p<0.0001) で13%のRR低下を示した.
- 脳卒中,あらゆる原因による死亡率,心血管疾患による死亡率については,有意な効果は認められなかった.
- 繊維剤はアルバミヌーリアの進行を14% (p=0.028) 減少させましたが,一般的に血清クレアチニンが増加しました.
結論:
- 繊維は,主に冠動脈イベント予防を通じて,主要な心血管イベントを効果的に軽減します.
- 繊維酸は,高リスクの個人および併合性脂質不全症患者にとって有益である可能性があります.
- 重篤な薬物関連有害事象の有意な増加は認められなかった.
関連する概念動画
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:17Ischemic Heart Disease: Overview
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...